Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2

doi:10.1084/jem.170.6.1931

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Lowell, C. A.
	Articles by Ahearn, J. M.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Lowell, C. A.
	Articles by Ahearn, J. M.


Social Bookmarking

	What's this?

ARTICLES

Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2

CA Lowell, LB Klickstein, RH Carter, JA Mitchell, DT Fearon and JM Ahearn
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.

Complement receptor type 2 (CR2;CD21), a member of the superfamily of proteins containing short consensus repeats (SCRs), is the B cell receptor for both the gp350/220 envelope protein of Epstein-Barr virus (EBV), and for the C3dg protein of complement. By analysis of CR2 deletion mutants and chimeras formed with CR1 (CD35) we determined that of the 15 SCRs in CR2, the NH2-terminal two SCRs are necessary and sufficient to bind both gp350/220 and C3dg with affinities equivalent to those of the wild-type receptor. The epitope for OKB-7, a mAb that blocks binding of both EBV and C3dg and shares with these ligands B cell-activating capabilities, also requires both SCR-1 and SCR-2, whereas mAbs lacking these functions bind to other SCRs. Thus, EBV, a polyclonal activator of B cells, has selected a site that is proximate or identical to the natural ligand binding site in CR2, perhaps reflecting the relative immutability of that site as well as its signal transducing function.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Young, K. A., Chen, X. S., Holers, V. M., Hannan, J. P. (2007). Isolating the Epstein-Barr Virus gp350/220 Binding Site on Complement Receptor Type 2 (CR2/CD21). J. Biol. Chem. 282: 36614-36625 [Abstract] [Full Text]
Morikis, D., Lambris, J. D. (2004). The Electrostatic Nature of C3d-Complement Receptor 2 Association. J. Immunol. 172: 7537-7547 [Abstract] [Full Text]
Prota, A. E., Sage, D. R., Stehle, T., Fingeroth, J. D. (2002). The crystal structure of human CD21: Implications for Epstein-Barr virus and C3d binding. Proc. Natl. Acad. Sci. USA 99: 10641-10646 [Abstract] [Full Text]
Hasegawa, M., Fujimoto, M., Poe, J. C., Steeber, D. A., Tedder, T. F. (2001). CD19 Can Regulate B Lymphocyte Signal Transduction Independent of Complement Activation. J. Immunol. 167: 3190-3200 [Abstract] [Full Text]
Sarrias, M. R., Franchini, S., Canziani, G., Argyropoulos, E., Moore, W. T., Sahu, A., Lambris, J. D. (2001). Kinetic Analysis of the Interactions of Complement Receptor 2 (CR2, CD21) with Its Ligands C3d, iC3b, and the EBV Glycoprotein gp350/220. J. Immunol. 167: 1490-1499 [Abstract] [Full Text]
Szakonyi, G., Guthridge, J. M., Li, D., Young, K., Holers, V. M., Chen, X. S. (2001). Structure of Complement Receptor 2 in Complex with Its C3d Ligand. Science 292: 1725-1728 [Abstract] [Full Text]
Krushkal, J., Bat, O., Gigli, I. (2000). Evolutionary Relationships Among Proteins Encoded by the Regulator of Complement Activation Gene Cluster. Mol Biol Evol 17: 1718-1730 [Abstract] [Full Text]
Clemenza, L., Isenman, D. E. (2000). Structure-Guided Identification of C3d Residues Essential for Its Binding to Complement Receptor 2 (CD21). J. Immunol. 165: 3839-3848 [Abstract] [Full Text]
Schneider-Schaulies, J. (2000). Cellular receptors for viruses: links to tropism and pathogenesis. J. Gen. Virol. 81: 1413-1429 [Full Text]
Hess, M. W., Schwendinger, M. G., Eskelinen, E.-L., Pfaller, K., Pavelka, M., Dierich, M. P., Prodinger, W. M. (2000). Tracing uptake of C3dg-conjugated antigen into B cells via complement receptor type 2 (CR2, CD21). Blood 95: 2617-2623 [Abstract] [Full Text]
Prodinger, W. M., Schwendinger, M. G., Schoch, J., Kochle, M., Larcher, C., Dierich, M. P. (1998). Characterization of C3dg Binding to a Recess Formed Between Short Consensus Repeats 1 and 2 of Complement Receptor Type 2 (CR2; CD21). J. Immunol. 161: 4604-4610 [Abstract] [Full Text]
Hein, W. R., Dudler, L., Marston, W. L., Landsverk, T., Young, A. J., Avila, D. (1998). Ubiquitination and Dimerization of Complement Receptor Type 2 on Sheep B Cells. J. Immunol. 161: 458-466 [Abstract] [Full Text]
Klickstein, L. B., York, M. R., Fougerolles, A. R.d., Springer, T. A. (1996). Localization of the Binding Site on Intercellular Adhesion Molecule-3 (ICAM-3) for Lymphocyte Function-associated Antigen 1(LFA-1). J. Biol. Chem. 271: 23920-23927 [Abstract] [Full Text]
Hebell, T, Ahearn, J., Fearon, D. (1991). Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science 254: 102-105 [Abstract]
Weisman, H., Bartow, T, Leppo, M., Marsh, H. Jr, Carson, G., Concino, M., Boyle, M., Roux, K., Weisfeldt, M., Fearon, D. (1990). Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249: 146-151 [Abstract]
Sisodia, S., Koo, E., Beyreuther, K, Unterbeck, A, Price, D. (1990). Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing. Science 248: 492-495 [Abstract]
Lin, H.-H., Stacey, M., Saxby, C., Knott, V., Chaudhry, Y., Evans, D., Gordon, S., McKnight, A. J., Handford, P., Lea, S. (2001). Molecular Analysis of the Epidermal Growth Factor-like Short Consensus Repeat Domain-mediated Protein-Protein Interactions. DISSECTION OF THE CD97-CD55 COMPLEX. J. Biol. Chem. 276: 24160-24169 [Abstract] [Full Text]